KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Debt (2016 - 2025)

Astrazeneca (AZN) has 3 years of Total Debt data on record, last reported at $27.8 billion in Q4 2025.

  • For Q4 2025, Total Debt fell 3.55% year-over-year to $27.8 billion; the TTM value through Dec 2025 reached $27.8 billion, down 3.55%, while the annual FY2025 figure was $27.8 billion, 3.55% down from the prior year.
  • Total Debt reached $27.8 billion in Q4 2025 per AZN's latest filing, down from $28.8 billion in the prior quarter.
  • Across five years, Total Debt topped out at $28.8 billion in Q4 2024 and bottomed at $27.5 billion in Q4 2023.
  • Average Total Debt over 3 years is $28.1 billion, with a median of $27.8 billion recorded in 2025.
  • Peak YoY movement for Total Debt: rose 4.91% in 2024, then fell 3.55% in 2025.
  • A 3-year view of Total Debt shows it stood at $27.5 billion in 2023, then grew by 4.91% to $28.8 billion in 2024, then fell by 3.55% to $27.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $27.8 billion in Q4 2025, $28.8 billion in Q4 2024, and $27.5 billion in Q4 2023.